

16 November 2022

ASX Announcement

Island Pharmaceuticals granted key Canadian patent for ISLA-101

- Island's lead asset, ISLA-101 granted key patent from the Canadian Intellectual Property Office (CIPO) covering a method of treating or preventing dengue and other mosquito borne viruses
- Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever.
- Around 390 million people are infected with dengue fever each year¹, representing a significant unmet need and opportunity.

MELBOURNE Australia, 16 November 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to announce that a key patent relating to the Company's lead drug candidate, ISLA-101, has been granted by the Canadian Intellectual Property Office (CIPO).

The Canadian patent grant entitled "INHIBITION OF FLAVIVIRUSES OR CHIKUNGUNYA VIRUSES USING RETINOIC ACID ANALOGUES" was issued under Canadian Patent No 2945825 and has an expiration date of 16 April 2034. The patent covers a method of treating or preventing dengue virus or other mosquito borne virus infections with ISLA-101. Island has licensed the IP portfolio, generated by Monash University.

CEO of Island Pharmaceuticals, Dr David Foster said, *"We are excited about the grant of this Canadian patent, which adds to Island's growing intellectual property portfolio and supports the broad applicability of ISLA-101 for different mosquito borne viruses. Increasingly there are reports about mosquito borne viral disease outbreaks in the news. These continue to represent indications of major unmet medical need, creating a strong market for new treatments like ISLA-101. This patent further protects our lead program, which is critical as we advance rapidly towards the commencement of clinical trials."*

This is the Company's first patent issued in Canada, adding to an estate for the same coverage in Australia, the United States, Brazil, and Singapore.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

¹ <https://www.worldmosquitoprogram.org/sites/default/files/2022-04/WMP%20dengue%20%281%29.pdf>



Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue² fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.